Equity Profile

CNTA

Centessa Pharmaceuticals plc

Health CareBiotechnology$6.3B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Centessa Pharmaceuticals plc is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs through its diverse pipeline of drug candidates.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.39

Revenue

Revenue figures will provide insight into the company's market performance and product development progress.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of $-0.52, which was worse than the expected $-0.38. This miss raised concerns about the company's financial trajectory.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Centessa to report a loss of $-0.39 per share with no revenue, reflecting ongoing challenges in its product pipeline.

Bull Case

If Centessa can show progress in its clinical trials or provide positive updates on its drug candidates, it may boost investor confidence and lead to a positive stock reaction.

Bear Case

Continued losses and lack of revenue could heighten concerns about the company's viability and lead to a significant drop in stock price.

Key Metrics to Watch

EPS

$-0.39

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures will provide insight into the company's market performance and product development progress.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of its clinical trials?

Investors will be closely watching for any signs of advancement in the drug pipeline, which could influence future revenue potential.

How does management plan to address the continued losses reported in previous quarters?

Understanding the company's strategy for financial recovery will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Centessa's pipeline to yield positive results, especially if recent clinical trials show promise.

Supporting Evidence

The options market is pricing a significant move, indicating that investors are expecting more than just a typical earnings report.

Historical data shows that the stock has reacted positively to unexpected updates in the past, despite recent losses.

Key Risk

If the company can provide positive updates on its clinical trials, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Centessa can turn around its financial performance and make progress in its drug development pipeline.

Bull Confirmed If

A narrower EPS loss than the expected $-0.39, indicating improved financial health.

Bear Confirmed If

An EPS loss greater than $-0.39, suggesting worsening financial conditions.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests a potential stock increase of around 0.04%, confirming a positive outlook.

In-Line / Cautious

A report in line with expectations may lead to a muted response, as investors await further clarity on the company's future.

Miss

If the company misses expectations, history suggests a potential decline of around 8.63%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any commentary on financial strategies to reduce losses.
3Insights into potential partnerships or collaborations.
4Management's outlook on future revenue generation.
5Responses to how the company plans to address investor concerns.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.39

Revenue

Revenue figures will provide insight into the company's market performance and product development progress.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of $-0.52, which was worse than the expected $-0.38. This miss raised concerns about the company's financial trajectory.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Centessa to report a loss of $-0.39 per share with no revenue, reflecting ongoing challenges in its product pipeline.

Bull Case

If Centessa can show progress in its clinical trials or provide positive updates on its drug candidates, it may boost investor confidence and lead to a positive stock reaction.

Bear Case

Continued losses and lack of revenue could heighten concerns about the company's viability and lead to a significant drop in stock price.

Key Metrics to Watch

EPS

$-0.39

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures will provide insight into the company's market performance and product development progress.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of its clinical trials?

Investors will be closely watching for any signs of advancement in the drug pipeline, which could influence future revenue potential.

How does management plan to address the continued losses reported in previous quarters?

Understanding the company's strategy for financial recovery will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Centessa's pipeline to yield positive results, especially if recent clinical trials show promise.

Supporting Evidence

The options market is pricing a significant move, indicating that investors are expecting more than just a typical earnings report.

Historical data shows that the stock has reacted positively to unexpected updates in the past, despite recent losses.

Key Risk

If the company can provide positive updates on its clinical trials, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Centessa can turn around its financial performance and make progress in its drug development pipeline.

Bull Confirmed If

A narrower EPS loss than the expected $-0.39, indicating improved financial health.

Bear Confirmed If

An EPS loss greater than $-0.39, suggesting worsening financial conditions.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests a potential stock increase of around 0.04%, confirming a positive outlook.

In-Line / Cautious

A report in line with expectations may lead to a muted response, as investors await further clarity on the company's future.

Miss

If the company misses expectations, history suggests a potential decline of around 8.63%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any commentary on financial strategies to reduce losses.
3Insights into potential partnerships or collaborations.
4Management's outlook on future revenue generation.
5Responses to how the company plans to address investor concerns.